Producer
North China Pharmaceutical (NCPC)
Second-largest penicillin enterprise globally and the largest Chinese producer of penicillin, amoxicillin, 6-APA, and streptomycin. Annual capacity: 7,000–8,000 tonnes antibiotics, 5,000 tonnes intermediates.
3
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
3 inputs North China Pharmaceutical (NCPC) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something North China Pharmaceutical (NCPC) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Penicillin & 6-APA (Core Antibiotic Chain)
65%Cephalosporins (7-ACA + Downstream)
25%Streptomycin & Other APIs
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
NCPC's 6-APA (6-aminopenicillanic acid) intermediate enters three structurally distinct supply chains that intersect with antibiotic resistance policy: (1) Human therapeutic antibiotics — 6-APA is converted to amoxicillin (most prescribed antibiotic globally), ampicillin, and piperacillin; used for bacterial infections in hospitals, primary care, and outpatient settings; (2) Veterinary antibiotics — the same amoxicillin and amoxicillin-clavulanate produced from NCPC 6-APA is used in veterinary medicine for livestock, pets, and aquaculture infection treatment; (3) Historically, agricultural growth promotion — penicillin-class antibiotics were used as growth promoters in pork and poultry production until bans in US (2017 VFD rules), EU (2006), and most developed markets; some developing countries still permit this use. The WHO's Critical Priority Pathogen List (ESKAPE organisms resistant to penicillin-class antibiotics) is directly connected to the overuse of antibiotics from the same supply chain NCPC dominates. The Chinese SOE that produces most of the world's antibiotic precursors also produced the antibiotics whose overuse created the antibiotic resistance emergency that now threatens modern medicine.
U.S. Food and Drug Administration ↗Origin2023
North China Pharmaceutical Group (NCPC) was founded in 1953 in Shijiazhuang, Hebei Province — established as part of China's First Five-Year Plan (1953-1957) with Soviet technical assistance to build domestic pharmaceutical manufacturing capacity. NCPC was built to produce penicillin for Chinese hospitals that had no domestic antibiotic supply during the Korean War period. The Soviet advisors who helped build NCPC's fermentation facilities transferred technology from Soviet pharmaceutical enterprises (themselves reverse-engineered from Western penicillin production processes captured from Germany after WWII). The Shijiazhuang pharmaceutical cluster around NCPC has grown to include multiple other Chinese antibiotic producers, making Hebei Province the dominant center of global antibiotic API production. NCPC is a state-owned enterprise under direct central government supervision — a Chinese SOE controlling a significant fraction of global hospital antibiotic supply. The US FDA has listed NCPC and related Chinese producers as sources of concern for US pharmaceutical supply chain security; Congressional reports have specifically named Chinese SOE antibiotic concentration as a national security risk.
North China Pharmaceutical Group Corp. ↗